PERSEPT 1: a phase 3 trial of activated eptacog beta for on‐demand treatment of haemophilia inhibitor‐related bleeding

Haemophilia A or B patients with inhibitors have been treated with FVIIa‐containing bypassing agents for over 20 years. However, due to uncertainty regarding dose response and thrombotic risk, the use of a gradual, titrated, minimal dosing strategy remains prevalent, potentially hampering early haemostasis.

[1]  G. Perret,et al.  Kinetic analysis and binding studies of a new recombinant human factor VIIa for treatment of haemophilia , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

[2]  J. Stevens,et al.  A Phase Ib, Dose Escalation Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Recombinant Coagulation Factor VIIa in Congenital Hemophilia A or B , 2016 .

[3]  D. Scott,et al.  Achievements, challenges and unmet needs for haemophilia patients with inhibitors , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[4]  E. Neufeld,et al.  Safety update on the use of recombinant activated factor VII in approved indications. , 2015, Blood reviews.

[5]  J. Oldenburg.  Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. , 2015, Blood.

[6]  L. Valentino.  Considerations in individualizing prophylaxis in patients with haemophilia A , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

[7]  J. Mahlangu,et al.  Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa , 2014, Journal of thrombosis and haemostasis : JTH.

[8]  E. Neufeld,et al.  Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg−1) rFVIIa doses across clinical trials and registries , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

[9]  N. Bihoreau,et al.  N-/O-glycosylation analysis of human FVIIa produced in the milk of transgenic rabbits , 2013, Glycobiology.

[10]  E. Santagostino,et al.  Real‐world outcomes with recombinant factor VIIa treatment of acute bleeds in haemophilia patients with inhibitors: results from the international ONE registry , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[11]  J. Mahlangu,et al.  Guidelines for the management of hemophilia , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[12]  M. Ovanesov,et al.  Unifying the mechanism of recombinant FVIIa action: dose dependence is regulated differently by tissue factor and phospholipids. , 2012, Blood.

[13]  F Forriol,et al.  Consequences of intra‐articular bleeding in haemophilia: science to clinical practice and beyond , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[14]  L. Valentino,et al.  Exploring the biological basis of haemophilic joint disease: experimental studies , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[15]  K. Kurnik,et al.  Identification and long‐term observation of early joint damage by magnetic resonance imaging in clinically asymptomatic joints in patients with haemophilia A or B despite prophylaxis , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[16]  D. Cooper,et al.  Patient/Caregiver‐reported recombinant factor VIIa (rFVIIa) dosing: home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE) , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[17]  A. Mumford,et al.  On‐demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and maintaining predictable efficacy with recombinant activated factor VII , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[18]  Christine A. Lee,et al.  Joint protection in haemophilia , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[19]  E. Neufeld,et al.  Exposure and safety of higher doses of recombinant factor VIIa ≥250 μg kg−1 in individuals with congenital haemophilia complicated by alloantibody inhibitors: the Haemophilia and Thrombosis Research Society Registry experience (2004–2008) , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[20]  Vera Mihajlovic‐Madzarevic.  Appendix B: Guidance for Industry—E6 Good Clinical Practice: Consolidated Guidance , 2010 .

[21]  S. Aksu,et al.  The value of early treatment in patients with haemophilia and inhibitors , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

[22]  P. Mathew,et al.  Recombinant activated factor VII for haemophilia patients with inhibitors undergoing orthopaedic surgery: a review of the literature , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

[23]  G. Young,et al.  Single 270 μg kg−1‐dose rFVIIa vs. standard 90 μg kg−1‐dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

[24]  J. Astermark,et al.  A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. , 2007, Blood.

[25]  M. Makris,et al.  Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors , 2006, Thrombosis and Haemostasis.

[26]  E. Santagostino,et al.  A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors , 2006, Journal of thrombosis and haemostasis : JTH.

[27]  T. Abshire.  The safety of recombinant factor VIIa: a reply to rebuttal , 2004 .

[28]  L. Aledort.  Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity , 2004, Journal of thrombosis and haemostasis : JTH.

[29]  G. Kenet,et al.  Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors , 2004, Journal of thrombosis and haemostasis : JTH.

[30]  G. Kenet,et al.  A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven®) , 2003, Journal of thrombosis and haemostasis : JTH.

[31]  Shapiro,et al.  A randomized, double‐blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors , 1998 .

[32]  J. Ingerslev,et al.  Clinical use of recombinant FVIIa (rFVIIa). , 1998, Transfusion science.

[33]  J. Oliver,et al.  Platelet activity of high‐dose factor VIIa is independent of tissue factor , 1997, British journal of haematology.

[34]  R. Stafford,et al.  Safety of recombinant activated factor VII in randomized clinical trials. , 2011, The New England journal of medicine.

[35]  U. Hedner.  Dosing with recombinant factor viia based on current evidence. , 2004, Seminars in hematology.

[36]  D. Monroe,et al.  Mechanism of action of high-dose factor VIIa: points of agreement and disagreement. , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[37]  P. Mannucci,et al.  A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group. , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

[38]  D. Monroe,et al.  Human monocytes support factor X activation by factor VIIa, independent of tissue factor: implications for the therapeutic mechanism of high-dose factor VIIa in hemophilia. , 1994, Blood.

[39]  P. Comp,et al.  Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. , 1993, Blood.